OnKure Therapeutics (OKUR) resets executive stock option prices in broad repricing
Rhea-AI Filing Summary
OnKure Therapeutics, Inc. reported multiple stock option adjustments for Chief Medical Officer Samuel Agresta effective August 7, 2026. The company implemented a one-time Option Repricing for employee options with exercise prices at or above $10.00 per share, resetting the exercise price of affected options, including Mr. Agresta’s, to $4.14 per share, the closing price of the Class A Common Stock on the effective date. There was no change to vesting schedules, expiration dates or the number of underlying shares. A Retention Period applies: if a repriced option is exercised before the earlier of February 7, 2028 or a Change in Control, the holder must pay the original, higher exercise price; otherwise the reduced $4.14 exercise price applies.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Agresta Samuel
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) F1 | 50,000 | $0.00 | $0.00 |
| Disposition | Employee Stock Option (right to buy) F3, F4, F2 | 18,588 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F2 | 18,588 | -- | -- |
| Disposition | Employee Stock Option (right to buy) F3, F4, F5 | 131,396 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F5 | 131,396 | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 199,984 shares (Direct)
Footnotes (5)
- F1. 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- F2. 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- F3. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
- F4. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.
- F5. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Key Figures
New exercise price after repricing: $4.14 per share
Repriced option block: 18,588 shares
Repriced option block: 131,396 shares
+3 more
6 metrics
New exercise price after repricing
$4.14 per share
Closing price of Class A Common Stock on August 7, 2026; reset exercise price for repriced options
Repriced option block
18,588 shares
Employee Stock Option previously at $13.99 exercise price, now subject to $4.14 exercise price and Retention Period terms
Repriced option block
131,396 shares
Employee Stock Option previously at $18.20 exercise price, now subject to $4.14 exercise price and Retention Period terms
New option grant size
50,000 shares
Employee Stock Option grant with $4.14 exercise price, vesting monthly after September 7, 2026
Retention Period end date
February 7, 2028
Latest date through which early exercise of repriced options requires paying original exercise price, absent a Change in Control
High-strike eligibility threshold
$10.00 per share
Minimum original exercise price for options to qualify for the one-time Option Repricing
Key Terms
Option Repricing, Retention Period, exercise price, Change in Control, +1 more
5 terms
Option Repricing financial
"The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing")"
Retention Period financial
"if an option holder exercises a repriced option before the end of a "Retention Period""
exercise price financial
"the exercise price of the repriced options, including the reported option, has been amended"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Change in Control financial
"ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Employee Stock Option financial
"security_title": "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
FAQ
What did OnKure Therapeutics (OKUR) disclose about Samuel Agresta’s stock options?
OnKure disclosed that Chief Medical Officer Samuel Agresta participated in a one-time Option Repricing effective August 7, 2026. His eligible options had their exercise prices reset to $4.14 per share, subject to specific vesting and retention conditions.
How many new or repriced options did Samuel Agresta receive at OnKure (OKUR)?
The filing reports option grants and repricings covering 50,000, 18,588, and 131,396 underlying shares of Class A Common Stock. The transactions reflect granting and repricing of existing employee stock options rather than open-market purchases or sales.
What is the new exercise price of repriced OnKure (OKUR) options for Samuel Agresta?
Repriced options, including those held by Samuel Agresta, now carry an exercise price of $4.14 per share. This corresponds to the closing price of OnKure’s Class A Common Stock on August 7, 2026, the effective date of the Option Repricing.
What happens if repriced OnKure (OKUR) options are exercised during the Retention Period?
If a holder exercises a repriced option during the Retention Period, they must pay the original exercise price, not $4.14. The Retention Period runs from August 7, 2026 until February 7, 2028 or an earlier Change in Control, whichever occurs first.
Which OnKure (OKUR) stock options were eligible for the Option Repricing?
The Option Repricing applied to outstanding options with exercise prices of $10.00 per share or more held by all continuing employees and certain other service providers of OnKure as of August 7, 2026, the effective date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
